EGF

EGF Informations sur la molécule

Nom anglaisEpidermal growth factorNombre de médicaments commercialisés0
Nombre de médicaments cliniques4Alias de la cibleEpidermal Growth Factor (Beta-Urogastrone),Beta-Urogastrone,Urogastrone,URG,EGF,HOMG4,Epidermal Growth Factor,Pro-Epidermal Growth Factor
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisEpidermal growth factor
Alias de la cibleEpidermal Growth Factor (Beta-Urogastrone),Beta-Urogastrone,Urogastrone,URG,EGF,HOMG4,Epidermal Growth Factor,Pro-Epidermal Growth Factor
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques4
Phase de R&D la plus avancéePhase 2 Clinical

EGF Liste de produits

  • Attribut

    Protein (7)Kits (2)

  • Bibliothèque de produits

    En ligne (9)

  • Espèces

    Human (8)Mouse (1)

  • Étiquette

    Mouse IgG Fc Tag (1)Fc Tag (1)His Tag (2)- (2)Tag Free (3)

  • Marqueur

    Unconjugated (6)- (2)AF488 Labeled (1)

EGFContexte de la molécule

Human epidermal growth factor (EGF) is also known as HOMG4 and  URG,and is a growth factor that plays an important role in the regulation of cell growth, proliferation, and differentiation by binding to its receptor EGFR. Epidermal growth factor can be found in human platelets, macrophages, urine, saliva, milk, and plasma. EGF is the founding member of the EGF-family of proteins. Members of this protein family have highly similar structural and functional characteristics. All family members contain one or more repeats of the conserved amino acid sequence. The biological effects of salivary EGF include healing of oral and gastroesophageal ulcers, inhibition of gastric acid secretion, stimulation of DNA synthesis as well as mucosal protection from intraluminal injurious factors such as gastric acid, bile acids, pepsin, and trypsin and to physical, chemical and bacterial agents. Because of the increased risk of cancer by EGF, inhibiting it decreases cancer risk.

EGFAlias de la molécule

EGF,URG,HOMG4

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian)CPGJ-602; 602; CPGJ602; CPGJ 602Phase 2 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co LtdColorectal Neoplasms
Details
DZD-6008DZD6008; DZD-6008Phase 2 ClinicalDizal (Jiangsu) Pharmaceutical Co LtdCarcinoma, Non-Small-Cell Lung
Details
Recombinant Human Epidermal Growth Factor Derivative Gel (Uni-Bio Science)Phase 1 ClinicalUni-Bio Science GroupWounds and Injuries
Details
ALX-2004ALX-2004Phase 1 ClinicalAlx Oncology IncCarcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details

Avis sur les produits

  • M***h2024-05-10
    1Mettre un like
    Optimizing a CSC protocol with various human derived cell lines, and need to order different components of CSC medias to test out. This product, in my opinion, did help me achieve slightly more spheres than in the other medias I tested. The product itself arrived quickly, was package super well, and was super easy to use and store in aliquots. It undergoes several testings and the information is easily accessible, and best of all it's not super expensive!
  • Informations sur la molécule
  • Liste de produits
  • Avis sur les produits
  • Informations sur les médicaments cliniques